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Objective:
 
 The objective of this study was to examine
the cost-effectiveness of a complementary treatment
with entacapone versus usual care only in patients with
Parkinson’s disease.
 
Methods:
 
 The setting for this study was the Nether-
lands. A Markov process model was constructed to
model the average quality-adjusted life years (QALYs)
and the costs of both treatments. The model examined
a period of 5 years in order to capture the influence of
symptom improvement and disease progression. Data for
the construction of the model were derived from pub-
lished literature, including large, multicenter, random-
ized clinical trials in patients with end-of-dose motor
 
fluctuations. Costs were obtained from published sources.
 
Results:
 
 The results of the baseline analysis showed that
the use of entacapone as complementary therapy in Par-
kinson’s disease slightly decreased the total average dis-
counted costs from NLG 111,317 to NLG 110,038,
while effectiveness increased from 2.42 to 2.56 QALYs
(a 6% increase). In addition, entacapone substantially
increased time without severe fluctuations by 0.63
years. Sensitivity analyses confirmed the robustness of
these findings.
 
Conclusion:
 
 The study shows that entacapone is a cost-
effective treatment in patients with Parkinson’s disease:
entacapone yields higher effectiveness in terms of both
effectiveness measures (time without severe fluctuations
and QALYs), while costs remain quite similar to those
for usual care. The additional drug costs for entacapone
are offset by reductions in other costs.
 
Keywords:
 
 cost-effectiveness, entacapone, Markov, Par-
kinson’s disease.
 
Introduction
 
Epidemiology and Pathology
 
Parkinson’s disease is a distinct neuropathologic
entity characterized by the loss of pigmented neu-
rons, most prominently in the substantia nigra,
with associated characteristic eosinophilic cyto-
plasmic inclusions (Lewy bodies). The clinical
hallmarks are bradykinesia, resting tremor, cog-
wheel rigidity, and postural reflex impairment.
This definition excludes all Parkinsonism of un-
known etiology and any disorder with multiple
system involvement or significant lesions of the
striatum, such as progressive supranuclear palsy,
olivopontocerebellar atrophy, multiple system at-
rophy, or striatonigral degeneration [1]. The crude
prevalence and incidence of idiopathic Parkinson’s
disease are estimated to be in the range of 100 to
300 and 1.5 to 20, respectively, in a population of
100,000, depending on race, age, geographical re-
gion and environmental setting of the study popu-
lation [1–3]. Prevalence increases with age, al-
though 10% of patients are under the age of 50
[4], and incidence rises with increasing age there-
after [5]. The Deprenyl and Tocopherol Antioxidative
Therapy for Parkinson’s Disease (DATATOP) study
showed that after an average of 8.2 years of observa-
tion, the overall death rate was unaffected by the
type of treatment and was about that expected for
an age-and gender-matched US population with-
out Parkinson’s disease [6].
 
Severity of Parkinson’s Disease
 
There are various scales to measure the severity of
Parkinson’s disease, including:
• the proportion of “on/off” time, a measure of
the existence of motor fluctuations, which will
be discussed in more detail in the next section;
• the Hoehn and Yahr scale, devised in the late
1960s, which is essentially a combination of clin-
ical signs and functional ability. The advantage
of using this scale seems to be that the stages of
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severity it addresses accurately represent pro-
gression of the disease, and are easily defined
by both patient and clinician. The Hoehn and
Yahr Scale consists of five disease stages vary-
ing from mild (stage I) to severe (stage V); and
• the Unified Parkinson’s Disease Rating Scale
(UPDRS) that was devised in the late 1980s.
Most signs are graded on a scale from 0 (nor-
mal) to 4 (most severe). Most of the grada-
tions are well defined and reduce subjective
and vague evaluations based on the physician’s
impressions of whether a symptom is mild,
moderate, or severe.
The UPDRS is divided into six sections:
• subscale I: mentation, behavior and mood;
• subscale II: activities of daily living;
• subscale III: motor examination;
• subscale IV: complications of therapy;
• subscale V: Hoehn and Yahr Scale; and
• subscale VI: Schwab and England Scale.
 
Pharmacotherapy of Parkinson’s Disease
 
Pharmacologic therapy to increase dopamine lev-
els within the brain is currently the most common
and effective treatment for symptoms of Parkin-
son’s disease. However, levodopa fails to stem dis-
ease progression and is frequently associated with
the development of abnormal motor responses. As
the number of years of treatment increases and the
disease inevitably advances, greater proportions of
responders to levodopa develop motor response
fluctuations (on/off effects). The percentage of
off time corresponds with the percentage of time
awake that the patient experiences abnormal in-
voluntary movements. Eventually the duration of
benefit from each dose of levodopa begins to de-
crease, an effect known as the wearing-off phenome-
non. After 3 to 5 years on levodopa, 50% of patients
begin to experience this wearing-off phenomenon
[7,8]. After 10 years of therapy, this phenomenon
is experienced by over 80% of patients [9].
Motor fluctuations can be improved to some ex-
tent when levodopa plasma concentrations are kept
stable, e.g., when levodopa controlled-release forms
(benserazide, carbidopa) are used, or by dividing in-
dividual doses with increased frequency of adminis-
tration. The controlled-release forms contain benser-
azide, which inhibits decarboxylation of levodopa.
These drugs produce a more constant rise in plasma
levodopa level, which is sustained for 3 to 4 hours
longer than that obtained with standard levodopa
preparations. However, all patients have to increase
their total daily dosage by 24% to 85% after some
time [10]. Although risk factors for development of
motor fluctuations include age at onset of disease,
levodopa dose, and duration of levodopa therapy,
the cause of levodopa-associated motor complica-
tions is not fully understood. Complications are be-
lieved to result mainly from the combination of dis-
ease progression and chronic levodopa therapy [11].
Abnormal involuntary movements are related
to both levodopa therapy and disease severity [12,
13]. They can be schematically separated into two
groups: choreiform/choreodystonic, and purely dys-
tonic. Choreiform/choreodystonic movements are
the most common and are always drug related.
These movements can occur at peak-dose, or at
onset and end-of-dose time between two intakes
of levodopa. Dystonic movements can be caused
by the disease process itself, but are frequently
drug related. Management of these different types
of dyskinesia is similar and difficult.
Dopamine agonists have been developed to over-
come the shortcomings of long-term levodopa ther-
apy. They can be classified into two groups: the
ergot derivatives and the newer nonergot deriva-
tives. Ergot derivatives include bromocriptine, per-
golide, lisuride and cabergoline; nonergot deriva-
tives include ropinirole, pramipexole and talipexole.
Numerous studies have documented the usefulness
of dopamine agonists in improving motor fluctua-
tions in patients with early Parkinson’s disease.
Unfortunately, dopamine agonist monotherapy is
rarely tolerated in patients with advanced disease.
As a result, these agents are most often used as
complementary treatment to levodopa.
Entacapone is a selective, reversible inhibitor of
catechol-O-methytransferase (COMT), a widely
distributed enzyme responsible for levodopa me-
tabolism. Entacapone has a favorable tolerability
profile and dosing that coincides with that of
levodopa for ease of use. Entacapone optimizes
the benefits of levodopa by delaying or preventing
motor fluctuations. Adverse events are related to
its ability to potentiate the effects of levodopa:
worsening of levodopa-induced dyskinesia, which
may be minimized in most patients by a down-
ward adjustment of the levodopa dosage. Clinical
trials with entacapone have shown that the use of
entacapone allows for a 10% to 12% reduction in
the dosage of levodopa [14,15]. Other advantages
compared with the dopamine agonists are that en-
tacapone has a fixed-dosage regimen and results in
immediate symptomatic benefit. Entacapone sub-
stantially reduced off time by 22% in the Nome-
comt trial [14] and by 17% in the Seesaw trial [15].
The overall conclusion of the entacapone clinical
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trials was that entacapone resulted in significant
clinical benefits in the treatment of parkinsonian
patients with end-of-dose motor fluctuations. En-
tacapone increased the duration of response to
levodopa and was well tolerated. The adverse
events associated with entacapone were dopamin-
ergic-related dyskinesia and nausea.
Our hypothesis for this study is that therapy
with entacapone for patients receiving levodopa
for Parkinson’s disease may result in improvements
clinically, economically, and in health-related qual-
ity of life compared with no entacapone therapy.
The decision to add a COMT inhibitor to levodopa
therapy may be based on a number of different fac-
tors. All patients may gain from reduction or delay
in motor fluctuations and a relatively low inci-
dence of adverse events, and older patients in par-
ticular may benefit from the ease of administra-
tion of entacapone.
 
The Health Care Burden of Parkinson’s Disease
 
Medical publications provide some information
about the economic impact of Parkinson’s disease
[7,16–21]. The relatively high prevalence of the
disease, its degenerative component, and its social
and familial implications lead to the hypothesis
that the economic impact of Parkinson’s disease
may be significant for health insurance systems,
for patient or family budgets, and for society in
general. Dodel et al. found a nonlinear positive re-
lationship between severity of the disease (Hoehn
and Yahr stages) and cost according to the Ger-
man National Health System in 1996 [22]. Pa-
tients incurred mean annual medical costs in 1995
US dollars ranging from $1250 in stage I to $6330
in stage V. Patients with fluctuations incurred
higher annual costs ($4260) than those without
fluctuations ($1960).
Parkinson’s disease is also likely to have a sub-
stantial impact on an individual’s health-related
quality of life. Disability derives predominantly
from motor fluctuations, rigidity, bradykinesia, and
postural instability, as well as from drug-induced dys-
kinesia. In addition, both the underlying neurodegen-
erative process and pharmacological treatment can
contribute to a variety of nonmotor symptoms in-
cluding depression, cognitive impairment, and auto-
nomic dysfunction. These symptoms intensify as the
disease progresses. The health consequences from
the patient’s perspective are fundamental to under-
standing the effectiveness of care. In a cross-sec-
tional study, Chrischilles et al. [23] showed that
strong associations exist between health-related
quality of life and degree of disability. This study
also confirmed findings of previously mentioned
studies that resource utilization is associated with
disability level.
 
Rationale
 
In the current climate of health care policy, strate-
gic choices have to be made, and the concept of
economic evaluation represents a major tool in the
health care decision-making process. In the Neth-
erlands, reimbursement decisions will probably be
based on economic data for innovative drugs that
cannot be clustered into existing drug groups.
The present study used a modeling technique to
compare the cost-effectiveness of complementary
therapy with entacapone versus no complemen-
tary therapy in patients who suffer from end-of-
dose motor fluctuations. The hypothesis was that
entacapone would result in a reduction of fluctua-
tions leading to a decrease in other direct medical
costs, and an increase in health-related quality of
life, which would offset the expected increase in
drug costs. In addition, it was hypothesized that
compared with usual therapy, the reduction in
motor fluctuations resulting from therapy with en-
tacapone would lead to short-term and long-term
reduction in disease severity (reduction in the pro-
portion of off time), increasing quality-adjusted
life years (QALYs), and reduction of total costs,
including direct medical costs.
 
Methods
 
To estimate the costs and effectiveness of comple-
mentary therapy with entacapone in patients with
Parkinson’s disease versus usual care, a model was
constructed using decision analysis [24,25]. Usual
care corresponds with the current standard ther-
apy for patients with severe fluctuations (
 

 
25%
off time), which consists of levodopa therapy for
all patients and extra add-on medication for some
(e.g., pergolide, bromocriptine, selegiline, amanta-
dine) (Table 1).
The incremental cost-effectiveness analysis used
in this study combined cumulative measures of
costs over time with a cumulative measure of ef-
fectiveness, resulting in incremental costs per clini-
cal benefit gained. The analysis was performed for
a hypothetical cohort of patients with Parkinson’s
disease whose clinical picture was characterized
by motor fluctuations. In general, the inclusion
criteria of the entacapone clinical trials defined the
hypothetical patient cohort: 1) patients in Hoehn
and Yahr stage between 1 and 4; 2) patients with
motor fluctuations; 3) levodopa-responsive patients;
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and 4) permitted use of amantadine, anticholin-
ergics, selegiline and/or dopamine agonists. The
analysis covered a period of 5 years. Effectiveness
was expressed as QALYs and time without 
 

 
25%
off time per day. The model included resource uti-
lization patterns associated with direct medical
costs (outpatient and inpatient care for the treat-
ment of Parkinson’s disease), and direct nonmedi-
cal costs. The setting of the study was that of the
Dutch health care system. Costs used in the model
were expressed in 1999 NLG. The cost valuation
was based on direct health care costs and direct
nonmedical costs. Indirect costs stemming from
working days lost were not included, because the
average age of patients with Parkinson’s disease
using levodopa/carbidopa or levodopa/benserazide
was 64 (Table 2), whereas the average age of retire-
ment in the Netherlands is 65 years. In addition,
the majority of patients with Parkinson’s disease
with motor fluctuations stop working during the
early stage of Parkinson’s disease, according to a
Dutch clinical expert who served as a consultant
for the study. Clinical and economic outcomes
were discounted at 4% from the second year on-
ward. The data sources were literature, including
clinical trials for entacapone, and official price
and tariff lists. An external clinical opinion leader
validated the methodology, including model struc-
ture, clinical treatment and assumptions.
 
Description of the Model
 
Markov process analysis techniques were used to
model the clinical and economic outcomes ac-
crued over a 5-year period with or without com-
plementary treatment with entacapone. The model
was constructed and analyzed using Data version
3.5 by TreeAge (TreeAge Software, Inc. Decision
Analysis by TreeAge [DATA] Software, Williams-
town, MA, 1996). The Markov process is conve-
nient when modeling the long-term evolution of
health states over successive time periods [26].
This type of model is deemed appropriate for use
in situations where events reoccur over time and
patients move among a finite number of health
states over the time period being considered
[27,28]. Because patients with Parkinson’s disease
are subject to disease progression and the number
of possible health states is finite, a Markov pro-
cess was preferred over standard decision-analytic
techniques. An advantage of a Markov process
model is that it allows modeling of Parkinson’s
disease progression beyond the follow-up of the
clinical trials.
A Markov process model describes several dis-
crete states of health in which a person can be at
 
Table 1
 
Drug utilization
 
Drug
Daily
dose
(mg)
%
receiving
drug
Daily
total
cost Source
Entacapone n.a. 7.75 Novartis
Levodopa
Monotherapy 745.0 100 2.66 Entacapone trials
With entacapone 658.0 100 2.34 Entacapone trials
Other
Pergolide 1.9 20 5.60 Entacapone trials
Bromocriptine 17.2 26 4.95 Entacapone trials
Selegiline 8.6 45 2.29 Entacapone trials
Amantadine 205.1 9 0.94 Entacapone trials
Mean (weighted
average) 3.51
Minimum 0.94
Maximum 5.60
 
Table 2
 
Baseline characteristics of study populations in entacapone trials
 
Nomecomt trial Seesaw trial
Characteristic Entacapone Placebo Entacapone Placebo
Number of patients at inclusion 85 86 103 102
Mean age (years) 62.67 
 

 
 7.6 62.8 
 

 
 8.0 64 
 

 
 8.0 63 
 

 
 9.7
Male gender (%) 55 55 67 63
Mean duration Parkinson’s disease (years) 10.2 
 

 
 4.8 11.3 
 

 
 4.8 10.7 
 

 
 4.9 11.3 
 

 
 6.4
Duration of wearing-off phenomenon 4.2 
 

 
 3.0 4.5 
 

 
 4.3
Mean duration levodopa treatment (years) 7.9 
 

 
 4.2 9.0 
 

 
 4.1 9.0 
 

 
 4.7 8.9 
 

 
 6.0
Mean duration of fluctuations (years) 4.2 
 

 
 3.4 4.7 
 

 
 3.5 4.2 
 

 
 3.0 4.5 
 

 
 4.3
Proportion of daily on time 62.7 
 

 
 14.6 63.8 
 

 
 15.8 60.0 
 

 
 15.2 60.8 
 

 
 14.0
Hoehn and Yahr stage:
1.0 0 0 1.0 1.0
1.5 11 8 2.9 1.0
2.0 45 49 44.7 49.0
2.5 21 23 21.4 18.6
3.0 20 19 26.2 24.5
4.0 3 1 3.9 5.9
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time t 
 

 
 
 
n
 
, as well as the states of health into
which the person may move at time t 
 

 
 
 
n
 
 
 

 
 1.
The progression from t 
 

 
 
 
n
 
 to t 
 

 
 
 
n
 
 
 

 
 1 is called a
cycle. All clinically important events are modeled
as transitions from one state to another state.
Probabilities are associated with each change be-
tween two states; these are termed transition prob-
abilities. Each transition probability is a function
of the state of health and the treatment. Our Markov
model is shown in Figure 1. The first branching
point on a tree is called a decision node, because it
corresponds to a choice of treatment: therapy with
or without entacapone. A decision node is repre-
sented as a square (
 

 
). The other branching points
in the figure indicate allowed transitions per cycle.
These branching points are called chance nodes,
because the transitions are beyond the control of
the physician. A small circle represents a branch-
ing point (
 

 
). Each state is assigned a utility, and
the overall contribution of this utility depends on
the length of time spent in the state. A utility can
be a clinical as well as an economic parameter. Us-
ing conventional principles of clinical decision
analysis, expected clinical and economic outcomes
are determined as a probability-weighted sum of
costs and outcomes occurring beyond the initial
treatment decision. A 6-month cycle was used in
the Markov model and the follow-up time was 5
years. The defined health states corresponded with
severity levels of Parkinson’s disease. In addition,
mortality was incorporated into the model by def-
inition of the health state dead. The states were:
 
• off time 
 

 
25%;
• off time 
 

 
25%; and
• dead.
The rationale behind the cut-off point of 25%
off time is that the study by Dodel et al. [7]
showed that:
• significant levels of decrease in utility values
were reached when patients had 
 

 
25% off
time; and
• an increase in costs was found if patients had
 

 
25% off time.
Transitions between health states may be cate-
gorized into:
• improvement: short-term improvement being
defined as a switch from 
 

 
25% off time to
 

 
25% off time; and
• progression: long-term disease progression be-
ing defined as a switch from 
 

 
25% off time to
 

 
25% off time.
In the model, all patients started in the health
state 
 

 
25% off time based on the average baseline
off time of the various treatment arms in the entaca-
pone clinical trials, which varied between 37% and
40% (Table 2). Hence, this range is based on group
means, not a range across individual patients.
 
Description of Transitions
 
In our analysis, a hypothetical cohort of persons
with Parkinson’s disease received usual therapy
Figure 1 Simplified structure of the Markov model.
 Cost Benefit: Entacapone in Parkinson’s Disease
 
321
 
with or without entacapone. The clinical trial data
showed that patients using entacapone showed an
improvement from 
 

 
25% off time to 
 

 
25% off
time, while patients receiving usual care showed
no improvement as treatment had already been
optimized to the extent possible in this treatment
group.
 
Entacapone.
 
During the first cycle, off time could
become higher or lower than the 25% cut-off
point which determined the transitions. At the end
of this cycle, the patient remained alive or had
died. When the patient remained alive there were
two possibilities:
• improvement: the patient moved to the health
state for 
 

 
25% off time; or
• no improvement: the patient remained in the
health state for 
 

 
25% off time.
Patients who did not improve in the first 6-month
cycle were assumed not to improve in subsequent cy-
cles in the base case; these patients either continued
to experience 
 

 
25% off time or died in subsequent
cycles. After each 6-month cycle, the possible transi-
tions for patients who had shown an improvement
in off time during the first cycle and who remained
alive were:
• no progression: the patient remained in the
health state for 
 

 
25% off time; and
• progression: the patient progressed to the
health state for 
 

 
25% off time.
 
Usual Care.
 
During the first cycle, there was no
improvement from 
 

 
25% off time to 
 

 
25% off
time. Hence, these patients remained in the health
state for 
 

 
25% off time for the entire 5-year pe-
riod unless they died.
 
Key Model Assumptions
 
There were a number of key assumptions upon
which the model was based:
• A 6-month cycle was used because this interval
closely approximated the follow-up period of
the clinical trials for entacapone. Follow-up
data for estimating the treatment effect of en-
tacapone were available from the 24- to 26-
week entacapone clinical trials [14,15]. Fol-
low-up data for dopamine agonists that fit the
structure of our model were also available for
approximately 6 months.
• The follow-up time (analytical horizon) was 5
years corresponding with literature [39].
• All patients continued their initial therapy for
the remainder of the follow-up period regard-
less of improvement or disease progression. Dis-
ease progression beyond the actual follow-up
period of the entacapone clinical trials was mod-
eled using various scenarios. In the base-case
analysis we assumed that beyond the actual fol-
low-up period of the current 6-month entaca-
pone clinical trials, the rate of disease progres-
sion for patients who improved on entacapone
was similar to the natural rate of disease pro-
gression.
• Clinical events during the first cycle (e.g., im-
provement) occurred at the middle of the cycle.
Therefore, we applied a half-cycle correction
for all clinical and economic outcomes.
• Annual mortality was based on the average life
expectancy of a hypothetical patient entering
the model, whose age was based on the aver-
age age of patients in the entacapone clinical
trials. Life expectancy was a weighted average
of life expectancy for men and women, which
was based on distribution of gender in the en-
tacapone trial population. It was assumed that
Parkinson’s disease did not alter life expect-
ancy, as shown in the DATATOP study for the
US population [6].
• Entacapone or other complementary therapy
did not reduce patients’ risk of mortality.
 
Effectiveness Assessment
 
The primary effectiveness measurements for the
alternative therapeutic strategies were:
• time without 
 

 
25% off time (years); and
• QALYs.
The concept of utility is derived from econom-
ics. It is a general concept for measuring the value
individuals attach to the consequences of various
actions, in this case the consequences of different
treatment options [30]. The goal of this measure-
ment technique is to obtain a numerical value that
represents the strength of the individual’s prefer-
ences for a particular outcome [31]. Utilities can
be used in a cost-utility analysis and results can be
presented as costs per QALY for each of the treat-
ment alternatives [32–35].
The utility assessment was based on the follow-
ing formula:
(1) Utility ts us×
s 1=
n
∑=
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where 
 
t
 
 is the number of cycles spent in a particu-
lar health state; and 
 
u
 
 is the utility of the parti-
cular health state (
 

 
25% off time or 
 

 
25% off
time) used to relate each health state to an average
QALY.
 
Cost Assessment
 
The cost assessment was based on the assignment
of fixed costs to the health states associated with a
6-month cycle. The costs of each health state were
determined by the resource utilization associated
with a health state: medical resource utilization
(e.g., medication, consultations and procedures)
and nonmedical resource utilization (e.g., social
services, home modifications).
Direct medical costs were analyzed using the
number of units of health care resources. The fol-
lowing health care resources were considered (Ta-
ble 3):
• medication, including prescription and over the
counter (OTC) consumption (dosage, form, du-
ration, indication);
• medical consultations (type, indication, special-
ists);
• laboratory and diagnostic tests and procedures
(type);
• hospitalizations (type, duration, service, indi-
cation);
• nursing home (type, duration, service, indica-
tion); and
• medical and nursing services and procedures
(type, indication).
In addition, direct nonmedical costs were in-
cluded. Examples are:
• equipment: cane;
• transportation: car or public transport;
• home modifications: home lift, hand rails, bath-
room; and
• community services: social worker.
 
Perspectives
 
The standard cost evaluation was performed from
the societal perspective according to the Dutch
pharmacoeconomic research guidelines. Reimburse-
ment rules were applied to specific items accord-
ing to the tariff lists: list prices of drugs, consulta-
tions, procedures (including laboratory tests), and
Table 3 Costs in 1999 NLG
Description Unit Cost (NLG) Unit Source
Inpatient care
Nursing home 200.00 Per diem COTG, 1999
Skilled nursing facility (wijkverpleging) 95.40 Daily tariff
Daycare (dagverpleging) 375.00 Per diem
Other if not included in per diem COTG, 1999
GP 38.00 Per consultation
Neurologist 116.00 Per consultation
Home physiotherapy 38.05  19.05 Per consultation
Therapeutic exercise (physiotherapy) 38.05 Per consultation
Massage 38.05 Per consultation
Ambulatory care COTG, 1999
Neurologist 116.00 Per consultation
GP 57.60 Per consultation
Internist 118.00 Per consultation
Orthopedic surgeon 50.50 Per consultation
Psychologist 95.40 Per consultation
Home nurse 95.40 Per consultation
Social worker 95.40 Per consultation
Procedures COTG 1999
ECG 40.00 Per procedure
EEG 164.00 Per procedure
X-ray 58.20 Per procedure
Cranial CT-scan 360.00 Per procedure
Cranial MRI 871.00 Per procedure
Acupuncture 38.05 Per procedure
Massage 38.05 Per procedure
Therapeutic exercise 38.05  19.05 Per procedure
Other aids
Home lift 2000.00 Per aid Market prices
Cane 100.00 Per aid Market prices
Hand rails 500.00 Per aid Market prices
Bathroom 5000.00 Per aid Market prices
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hospitalization (per diem charge). Value-added taxes
(VAT) were not included in the costs, because
these constitute transfer payments for society.
Analysis
The standard analysis from the societal perspec-
tive represents:
• the expected average effectiveness: time with-
out severe fluctuations, QALYs;
• the total costs per patient, including cost distri-
bution: direct medical and nonmedical costs.
The cost distribution of the direct medical costs
is also presented separately.
Clinical and economic outcomes were discounted
because the time horizon of the model extended be-
yond a period of 1 year. The discount rate was based
on the recommended 4% according to the Dutch
pharmacoeconomic guidelines [36]. The discount
rate was varied in sensitivity analyses.
Univariate sensitivity analysis was based on a
modification of the basic clinical assumptions and
economic assumptions in the clinical outcome
model in order to test the stability of the conclu-
sions of the analysis over a range of assumptions,
probability estimates, and value judgments. This
procedure entailed changing one of the model pa-
rameters through a range of plausible values and
assessing the effect on the overall outcome of the
foldback analysis. The range of each parameter
depended on variance in data from clinical trials,
literature, and official tariff lists. If the preferred
strategy remained stable over the entire range of
plausible values for a given parameter, then the
model was insensitive to values within the range
of that parameter. A sensitivity analysis was per-
formed for the following input variables in the
model: probabilities of improvement for entaca-
pone; disease progression; cost of complementary
antiparkinsonian medication; and discounting. The
range of the variables has been defined in Table 4.
We added Monte Carlo simulation based on num-
ber of potential candidates for use of entacapone
in the Netherlands (n  7000).
Data Sources
The data sources and collection were based on the
following:
The probabilities of clinical events were based
on entacapone clinical trials [14,15] and other
published literature. Probabilities of clinical events
are generally out of the control of the physician
(e.g., the probability of disease progression from
25% to 25% off time) [24].
The utilities were obtained from prospectively
collected data from a utility study specifically de-
signed for this project [37].
Units of resource utilization were derived from
a cross-sectional study.
Direct medical costs, which involved estimating
the units of health care utilization and their prices/
tariffs (product of unit and price), were derived
from official lists.
Probabilities
Probabilities of improvement during the first cycle
were derived from the entacapone clinical trials
[14,15]. The fixed input value for entacapone was
the mean of the probabilities of improvement
from these trials; the results from the two trials
provided a range for use in sensitivity analysis.
The probability of improvement was based on the
proportion of patients who initially had 25%
off time who improved to 25% off time. Those
Table 4 Transition probabilities
Description Reduction in off time (%) Value Range Source
Improvement from 25% to 25% off time in cycle 1:
Entacapone
Seesaw 14.0 0.208 [14,15]
Nomecomt 22.0 0.464 [14,15]
Mean 0.336 0.208–0.464 [14,15]
Usual care 0.000
Progression from 25% to 25% off time in cycles 2 and higher based on:
Duration of fluctuations 0.281 Max [38]
Duration of levodopa therapy 0.090 Min [38]
Mean 0.179 [38]
Life expectancy (years):
Men (64%) 14.4 0.035
Women (36%) 19.0 0.027
Weighted by gender 0.032 0.027–0.035
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data were secondary outcomes in the entacapone
clinical trials (Table 4).
The probabilities for disease progression in the
base-case analysis for subsequent cycles were de-
rived from the duration of fluctuations and dura-
tion of levodopa therapy of the patients at inclusion
in the cross-sectional MEDTAP utility study [38].
The average duration of progressing from 25%
off time to 25% off time was the difference in
the average duration of levodopa therapy between
patients in health state 25% off time and 25%
off time. This figure can be transformed into an
annual probability by taking the reciprocal of this
difference and subsequently adjusting to a cycle
time of 6 months [38]. The average duration of
levodopa therapy in patients with 25% off time
currently (including time spent in state 25% off
time), was 11.38 years, while the average duration
of levodopa therapy in patients with 25% off
time was 5.53 years. Hence, the average time to
progress from 25% off time to 25% was the
difference between 11.38 and 5.53 years (5.85
years). The calculation of the annual rate (0.17)
was based on the reciprocal of the time to proceed
from one state to another state, adjusted to a
6-month cycle (0.09 years). We also used an alter-
native variable, duration of fluctuations, as experi-
enced by patients in the cross-sectional utility study
to calculate disease progression. We applied the
same method as that described above, taking the dif-
ference (2.07 years) in duration in fluctuations be-
tween patients with 25% off time versus those
with 25% off time. The annual rate (0.48) was ad-
justed to a 6-moynth transition probability of 0.28.
These calculations showed a substantial differ-
ence in 6-month probabilities: 0.28 for the calcula-
tion based on difference in duration of fluctuations
and 0.09 for the calculation based on difference in
duration of levodopa therapy. This may be due to
a subjective underestimation by patients of dura-
tion of fluctuations; i.e., patients may overlook
symptomatic control of fluctuations. The fixed in-
put value was the average of the probabilities de-
rived from the difference in duration of fluctua-
tions and duration of levodopa therapy [39]. Had
both methods yielded similar probabilities, the
model would be considered more robust. Because
of the difference in outcomes, there is a level of
uncertainty associated with this variable. Therefore
we performed a sensitivity analysis varying the
rate between these two values in order to address
this uncertainty.
The probability of 6-month mortality was based
on the average life expectancy of a hypothetical
patient entering the model, whose age was based
on the average age of patients in the entacapone
clinical trials. We assumed that treated Parkinson’s
disease did not alter life expectancy, which was
shown in the DATATOP study for the US popula-
tion [6]. Calculation of the 6-month probability of
mortality was based on a method by Beck that
takes the reciprocal of life expectancy, adjusted to
a cycle time of 6 months [26].
Utilities
The utilities for the different health states were de-
rived from a MEDTAP utility study, which was
performed alongside this modeling study in the
United States [38]. The classification of disease se-
verity in this study was based on the health states
in our model. The underlying assumption was that
the function between percentage of the day with
fluctuations (off time) and utility may be extrapo-
lated from the United States to the Netherlands,
assuming that clinical outcomes are not country
specific [29]. The utilities of the Markov health
states were determined using the Standard Gamble
(SG) method. The results are shown in Table 5.
Resource Utilization
The drug utilization for levodopa and other anti-
Parkinson medications, including dopamine ago-
nists, were derived from the entacapone clinical
trials, which incorporated the lowering of levo-
dopa due to entacapone (Table 1). The other re-
source utilization for the different health states
was based on a German cross-sectional study (Ta-
ble 6) [7]. The defining characteristic of a cross-
sectional study is that the basic state of each per-
son in the evaluation is examined at one time
point. In this study all relevant units of resource
utilization in the 3 months preceding the study visit
were collected for each patient. Since the model
employs a 6-month cycle, we doubled the 3-month
resource utilization data to estimate 6-month re-
source utilization.
Costing
Costing was performed from the societal perspec-
tive. Market prices, where available, were used to
Table 5 Utility values based on the Standard Gamble 
method
Off time per day Fixed input value Minimum Maximum
25% off time/day 0.79 0.75 0.86
25% off time/day 0.65 0.55 0.76
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evaluate opportunity costs (i.e., costs of forgone
opportunities as a result of investment in a specific
health care strategy). In the absence of available
costs, tariffs were used as an approximation (Ta-
ble 3):
• Drug prices were derived from the Taxe 1999
[40].
• Consultations, procedures and hospitalization
costs were derived from the COTG 1999 [41].
• Nursing costs were derived from the COTG
1999.
• Transportation costs were valued according to
the national allowance per km (CBS) [42].
• Costs for home medications and other non-
medical costs were based on market prices.
Results
The DATA model was rolled back and calculated
to give an expected value for cost and QALYs per
patient. Sensitivity analyses were performed on
the main probabilities and outcomes in order to
ascertain the robustness of the conclusions.
Table 7 summarizes the clinical and economic
outcomes associated with a treatment with entaca-
pone compared with usual care alone. The average
discounted QALY based on the SG method was
2.42 without entacapone and 2.56 with entaca-
pone, which is a 6% increase. Entacapone sub-
stantially increased the time without 25% off
time by 0.63 years.
Entacapone slightly decreased the total average
discounted costs from NLG 111,317 to NLG
110,038. The direct medical costs are not higher
with entacapone than with usual care (89,514
NLG vs. 89,530 NLG). Table 8 shows the distri-
bution of the direct medical costs; hospitalization
is the main cost driver of usual care. The addi-
tional drug costs for entacapone are offset by re-
ductions in other costs, especially inpatient costs.
The data in Table 7 indicate that entacapone is
dominant over usual care, because entacapone yields
higher effectiveness in terms of both effectiveness
measures (time without 25% off time and QALYs),
while the costs do not increase. The costs per year
without 25% off time were NLG 27 and NLG
2031 based on direct medical and total costs, respec-
tively.
Sensitivity analyses were performed on the
main probabilities and cost assumptions in order
to test the robustness of the cost-effectiveness re-
sults. Table 9 shows the results of the sensitivity
analyses for the probabilities of improvement for
entacapone, disease progression, the costs of med-
ication other than levodopa therapy, discounting,
and mortality. The disease progression was varied
in both the entacapone and usual-care arms in or-
der to test the sensitivity of natural variance in dis-
ease progression. This table shows that entaca-
pone is dominant for all parts of the range given in
the table. Hence, the model can be considered to
be insensitive to changes in variables. Finally, we
added a first order Monte Carlo simulation based
on the number of potential candidates for use of
entacapone in the Netherlands (n  7000) (Table
10), which shows that there is a probability of
94.9% that entacapone will be cost-effective in
real practice.
Discussion
This study examined the cost effectiveness of com-
plementary therapy with entacapone compared
with usual therapy in patients with Parkinson’s
Table 6 Costs for each health state in 1999 NLG
Direct medical costs
Off time Consultations Physiotherapy Diagnostic procedures Inpatient care Total Total nonmedical costs Total costs
25% off time/day 587 1,631 48 0 2,266 1,743 4,009
25% off time/day 704 3,487 42 6,560 10,793 2,745 13,538
Table 7 Results of the Base Case Analysis: Costs and Effectiveness*
Costs (NLG)
Outcome Medical Nonmedical Total Years without 25% off time QALY (Based on Standard Gamble)
Usual care 89,530 21,786 111,317 0.00 2.42
Entacapone 89,514 20,525 110,038 0.63 2.56
*Discounted at 4%.
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disease who experience motor fluctuations in the
Dutch health care setting. Usual therapy was de-
fined as levodopa with or without additional med-
ication (excluding entacapone). The analysis re-
vealed that entacapone was cost-effective in the
treatment of patients with Parkinson’s disease who
experience severe motor fluctuations (25% off
time). Entacapone yields improved effectiveness in
terms of both effectiveness measures (time without
25% off time and QALYs), while the costs re-
main quite similar to usual care. The additional
drug costs for entacapone are offset by reductions
in other costs, especially inpatient care, which was
an important cost driver. Sensitivity analysis showed
that the outcomes of the model were robust.
The results of any modeling exercise need to
be treated with some degree of caution. Decision-
analytic techniques, upon which our Markov model
is based, have several weaknesses. Various data
sources were used for the model, which all have
their pros and cons from a health-economic per-
spective [29]. Among the model limitations is the
fact that our literature review does not necessarily
represent real clinical practice, as much of the lit-
erature examined was based on data from clinical
trials. Data from clinical trials do not necessarily
have a high degree of external validity since the re-
sults are often contingent upon protocol adher-
ence, a situation that may not be easily replicated
outside the trial setting. There are also a number
of methodological issues associated with the use of
the other data sources, which need to be addressed
in more detail.
The data collection in the cross-sectional cost-
of-care study relied on the memory of the patient,
as well as the patient’s medical records, laboratory
tests, medications, and so on. Instead of retrospec-
tive data collection, it would have been preferable
to have data collected prospectively during a 3-month
period following enrollment. Both the prospective and
retrospective approaches have pros and cons. The risk
of the retrospective approach is that collection of re-
sources may be incomplete because of reliance on the
memory of the patient or other reasons. For in-
stance, in the case of switching between in- and
outpatient care, data were derived from different
medical records. The risk of the prospective ap-
proach is the introduction of a potential bias both
for the patient and the physician. For example,
physicians may adjust their treatment patterns to
ideal care, which may reduce the external validity
of the prospectively collected data (e.g., an overes-
timation of resources). Hence an advantage of the
retrospective approach is the external validity of
the data. In this study, inpatient care was an im-
portant cost driver due to differences in inpatient
costs between patients in the two health states.
This corresponds with the results of a recent US
study that assessed the cost-effectiveness of enta-
capone in the United States [43]. The average 6-
month costs for hospitalization were $6 and $297
for patients with 25% and 25% off time, re-
spectively; the average 6-month costs for other in-
stitutional care were $73 and $2397, respectively.
The utilities in our model were derived from a
prospective study [38] based on clinical treatment
practice without use of entacapone. The utility of
a health state is a function of both underlying dis-
ease and adverse events associated with treatment.
In our model, we valued the health states corre-
sponding with entacapone according to the utili-
ties of health states with usual therapy. Thus, the
assumption in our model was that treatment with
entacapone did not affect the utility of health
states. Hence, the utilities did not take into ac-
count a potential higher utility of health states as-
sociated with entacapone treatment. Consequently,
the current analysis may lead to an underestima-
tion of QALYs for entacapone. We also did not in-
Table 8 Results of the base-case analysis: direct medical 
costs distribution
Costs (NLG)*
Outcome Drugs Consultaion Other Inpatient Care
Usual care 3870 5587 28008 52064
Entacapone 14588 5440 25679 43806
*Discounted at 4%.
Table 9 Sensitivity analysis: incremental cost-effective ratios (ICRs)*
Sensitivity analysis Value range ICR—Total costs ICR—Medical costs
Rate of improvement with entacapone 0.207–0.464 Dominant Dominant
No discounting 0% Dominant Dominant
DTC of comedication 0.943–5.60 Dominant Dominant
Mortality rate 0.026–0.035 Dominant Dominant
Disease progression rate 0.017–0.474 Dominant Dominant
*Discounted at 4%.
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clude the costs associated with treatment of adverse
events, which may underestimate the costs for dopa-
mine agonists, in particular. Finally, in the base-case
analysis, we did not include the expected positive im-
pact of entacapone on disease progression owing to
the impact of its favorable safety profile.
The recent Dutch pharmacoeconomic research
guidelines only recommend the inclusion of costs
of lost productivity associated with working days
lost [37], which are negligible in our study popula-
tion (average age: 64 years). We felt that estimat-
ing these costs would make our results less cred-
ible and therefore excluded these costs from our
analysis. In addition, there is no consensus yet among
scientists on how to address time spent on unpaid ac-
tivities and time spent by caregivers. Therefore, the
current analysis can be considered an underestima-
tion of the true societal benefits of using entacapone.
Although there are some limitations to the mod-
eling technique, there are also advantages. The
ideal design to demonstrate the possible health
outcome and costs associated with complementary
treatment with entacapone would be a naturalistic
prospective study. However, a prospective study
in Parkinson’s disease would require a follow-up
for a period of at least 5 years, which was not fea-
sible. The use of a Markov model allowed us to
extrapolate clinical outcomes beyond the duration
of the existing clinical trials. Sensitivity analyses
were performed on critical input variables and an
extra scenario analysis was performed on reduc-
tion of disease progression with entacapone.
We took a large range for disease progression
in order to deal with the uncertainty associated
with extrapolation. The results of this sensitivity
analysis showed that outcomes of the model ap-
pear to be robust, which shows that uncertainty in
the method of extrapolation is limited.
Conclusion
The results of this study show that complementary
treatment with entacapone in Parkinson’s disease
patients who experience off time may be justified
from a health-economic perspective. Entacapone
is cost-effective when compared with usual ther-
apy. The increase in effectiveness was marginal for
QALYs, but substantial for time with less than or
equal to 25% off time. The use of entacapone re-
duced both direct medical and direct nonmedical
costs.
Source of funding: Novartis Pharma B.V., Arnhem, The
Netherlands.
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